Latest news

Debiopharm Leverages Risklick’s AI-Powered Solution to Improve Protocol Development Efficiency

Debiopharm Licenses SunRock Biopharma’s anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512

Debiopharm Joins The Working Group Of The Naipo Initiative: Transforming Cancer Care With Artificial Intelligence

Debiopharm’S Pamorelin® Receives Swiss Approval for subcutaneous Administration, Enhancing Treatment Flexibility for Prostate Cancer Patients

Debiopharm Pushes The Boundaries Of Innovation In Antibiotic Development Against Gonorrhea With First-in-human Debio 1453 Trial

Released by Repare Therapeutics: Repare Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

10e Challenge Qualité de vie du patient : cinq projets innovants récompensés, cap vers la finale !

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent…

Debiopharm’s ADC Research Gains Momentum with Launch of First-In-Human Trial Assessing Debio 1562m in Acute Myeloid Leukemia Patients